Nanomaterials for T-cell cancer immunotherapy
Related Experiment Video
Updated: Nov 21, 2025
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Ningqiang Gong1, Neil C Sheppard2,3, Margaret M Billingsley1
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with three approved products for B-cell malignancies and a large pipeline of treatments in clinical trials. However, there are several challenges to their broad implementation. These include insufficient expansion of adoptively transferred T cells, inefficient trafficking of T cells into solid tumours, decreased T-cell activity due to a hostile tumour microenvironment and the loss of target antigen expression. Together, these factors restrict the number of therapeutically active T cells engaging with tumours. Nanomaterials are uniquely suited to overcome these challenges, as they can be rationally designed to enhance T-cell expansion, navigate complex physical barriers and modulate tumour microenvironments. Here, we present an overview of nanomaterials that have been used to overcome clinical barriers to T-cell-based immunotherapies and provide our outlook of this emerging field at the interface of cancer immunotherapy and nanomaterial design.
Insights
Nanomaterials show promise in overcoming key challenges in T-cell immunotherapies for cancer. These materials can enhance T-cell function, trafficking, and survival within the tumor microenvironment, improving treatment efficacy.
Area of Science:
- Oncology
- Nanotechnology
- Immunology
Background:
- T-cell-based immunotherapies are a promising cancer treatment modality with approved products and an extensive clinical pipeline.
- Clinical implementation faces challenges including insufficient T-cell expansion, poor tumor trafficking, hostile tumor microenvironments, and antigen loss.
- These limitations restrict the number of active T cells reaching and engaging with tumors.
Purpose of the Study:
- To review the application of nanomaterials in overcoming clinical barriers for T-cell immunotherapies.
- To provide an outlook on the intersection of cancer immunotherapy and nanomaterial design.
Main Methods:
- Overview of existing literature on nanomaterials used in T-cell immunotherapy.
- Analysis of how nanomaterials address specific clinical challenges such as T-cell expansion, trafficking, and tumor microenvironment modulation.
Main Results:
- Nanomaterials can be engineered to enhance T-cell expansion and improve their ability to traffic into solid tumors.
- Rational design of nanomaterials allows for modulation of the tumor microenvironment to enhance T-cell activity.
- Nanomaterials offer a versatile platform to address multiple limitations of adoptive T-cell therapy.
Conclusions:
- Nanomaterials present a powerful strategy to enhance the efficacy of T-cell-based cancer immunotherapies.
- Further research at the interface of nanomaterial design and immunotherapy holds significant potential for future cancer treatments.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...